RA
VRTX icon

RiverPark Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

RiverPark Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-393
Closed -$44.6K – 150
2024
Q4 		$44.6K Buy
393
+291
+285% +$135K 0.04% 113
2024
Q3 		$47.4K Sell
102
-2
-2% -$961 0.04% 117
2024
Q2 		$48.7K Sell
104
-28
-21% -$12.2K 0.04% 112
2024
Q1 		$55.2K Buy
+132
New +$55.8K 0.05% 110

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RiverPark Advisors's VRTX Position: Q1 2025 in Review

RiverPark Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 393 shares — an estimated $44.6K sold.

RiverPark Advisors first reported a position in VRTX in Q1 2024 and held it in 4 quarters. The position peaked at $55.2K in Q1 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • RiverPark Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • RiverPark Advisors sold 393 Vertex Pharmaceuticals shares in Q1 2025, an estimated $44.6K.
  • RiverPark Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • RiverPark Advisors's Vertex Pharmaceuticals position peaked at $55.2K in Q1 2024.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on RiverPark Advisors's 13F filing for Q1 2025, filed 12 May 2025.